Company’s latest report reveals future plans, powered by efforts to divert more of its air shipments to sea.
Pharmanovia, a global pharmaceutical company that commercializes novel medicines and expands the lifecycle of established medicines, has increased its pledge to shift 40% of its air shipments to sea this year—a topic covered extensively at this year’s LogiPharma Europe—and 75% by the end of 2028.
The company made the commitment while also revealing the progress made toward achieving its environmental, social, and governance (ESG) initiatives in its new Sustainability Report. Its air-to-sea pilot scheme, which focuses on its Spain-to-Australia freight route, cut an estimated 470,000 kg in potential CO2 emissions in 2022, which reduced Scope 3 upstream transport emissions—those that are not produced by the company itself, and not the result of activities from assets owned or controlled by them, but by those that it is indirectly responsible for, up and down its value chain—by 18%.
Other highlights from the report include:
“… Our purpose is to improve the lives of patients globally, which is why setting meaningful targets to reduce our environmental impact is critical, to build a sustainable future for patients and the sector,” says James Burt, CEO, Pharmanovia. “We look forward to working with our partners within our supply chain to ensure we are all held to the most rigorous of environmental standards.”